NextCure, Inc.
Close on Oct 19, 2026
- Market cap
- $30.11M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
About NextCure
Pharmaceutical Preparations, SIC 2834
NextCure, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing targeted therapies, particularly antibody-drug conjugates, to treat cancer patients whose disease progresses or fails to respond to existing treatments. The company focuses on biological pathways, biomarkers, and cellular interactions within the tumor microenvironment. Its lead product candidates in Phase 1 clinical development include SIM0505, an antibody-drug conjugate directed against cadherin-6, and LNCB74, an antibody-drug conjugate targeting B7-H4. Additionally, the company is seeking strategic partners to develop its other clinical oncology candidates and preclinical non-oncology programs. Because its therapeutics are investigational biologics in clinical trials, the company does not yet market commercial products to paying customers.
The company operates globally through collaborative licensing and co-development partnerships spanning the United States, China, and other international regions. It maintains a dedicated, single-use current Good Manufacturing Practice production facility with a capacity of 2,000 liters, although internal manufacturing operations were paused following an operational restructuring. The provided text does not identify NextCure's headquarters location.
Summary of the business section of NextCure's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NextCure, Inc.
- Headquarters
- Baltimore, MD
- Address
- 2850 Quarry Lake Drive, Suite 280 21209
- Phone
- (240) 399-4900
- Website
- nextcure.com
- Employees
- 40, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst& Young LLP, Baltimore, Maryland
Stock & identifiers
- Ticker
- NXTC
- Exchange
- Nasdaq
- IPO date
- May 9, 2019
- Shares outstanding
- 5M, Jul 31, 2026
- Public float
- $12.60M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-12 reverse, Aug 7, 2025; 1-for-12 reverse, Jul 14, 2025
- SEC CIK
- 1661059
- CUSIP
- 65343E207
- ISIN
- US65343E2072
- LEI
- 549300Y5PR6RJR1STI24
- EIN
- 47-5231247
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael Richman | President & CEO, Director | 385,869 |
| Udayan Guha | Chief Medical Officer | – |
| Kevin G. Shaw | Sr VP, General Counsel | – |
| Sourav Kundu | Sr VP, Dev. & Mfg. | – |
| Timothy Mayer | Chief Operating Officer | – |
| Steven P. Cobourn | Chief Financial Officer | – |
| Sol Langermann | Chief Scientific Officer | 37,342 |
| Elaine V. Jones | Director | – |
| Anne Elizabeth Borgman | Director | – |
| Ellen Feigal | Director | – |
| Stephen W. Webster | Director | – |
| John G. Houston | Director | – |
| David S. Kabakoff | Director | 62,237 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Michael Richman | $941.69K | $1.07M | $636.21K | $84 | – |
| FY2024 Michael Richman | $1.51M | $1.14M | $876.46K | $55 | – |
| FY2023 Michael Richman | $1.04M | $885.07K | $689.76K | $81 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 40 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 18, 2026 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Feb 3, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 9, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| May 8, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |